Sol-Gel Technologies (NASDAQ:SLGL) Stock Rating Lowered by Raymond James

Sol-Gel Technologies (NASDAQ:SLGL) was downgraded by investment analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a research note issued to investors on Monday, MarketBeat.com reports. They currently have a $4.00 price objective on the stock, down from their previous price objective of $6.00.

Separately, HC Wainwright dropped their target price on Sol-Gel Technologies from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, May 20th.

Sol-Gel Technologies Stock Down 4.4 %

NASDAQ:SLGL opened at $0.45 on Monday. The stock has a fifty day simple moving average of $0.70 and a 200 day simple moving average of $0.86. The firm has a market capitalization of $12.51 million, a price-to-earnings ratio of -0.54 and a beta of 1.54. Sol-Gel Technologies has a 1-year low of $0.33 and a 1-year high of $2.99.

Sol-Gel Technologies (NASDAQ:SLGL) last announced its earnings results on Friday, August 16th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.27. The company had revenue of $5.43 million during the quarter, compared to analysts’ expectations of $1.06 million. Sol-Gel Technologies had a negative net margin of 1,329.13% and a negative return on equity of 56.20%. Equities analysts predict that Sol-Gel Technologies will post -0.83 earnings per share for the current year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.